Covid-19 roundup: Pfiz­er-BioN­Tech ask for kid boost­er EUA; No­var­tis, Mol­e­c­u­lar Part­ners may need an­oth­er tri­al for pan­dem­ic ther­a­py

As both the de­bate and pres­sure re­main around giv­ing the youngest chil­dren a first dose of the Covid-19 vac­cine, Pfiz­er and BioN­Tech are mov­ing ahead with sub­mit­ting an EUA for a Covid-19 vac­cine boost­er dose in chil­dren ages five through 11. There are al­so plans to sub­mit their da­ta to the EMA and oth­er reg­u­la­to­ry bod­ies in the com­ing weeks.

The da­ta demon­strate an in­crease in SARS-CoV-2 Omi­cron vari­ant and wild-type strain neu­tral­iz­ing titers fol­low­ing a boost­er dose of the Pfiz­er-BioN­Tech Covid-19 vac­cine com­pared to two dos­es, the com­pa­nies say. Those da­ta re­in­force the po­ten­tial func­tion of a third dose of the vac­cine in main­tain­ing high lev­els of pro­tec­tion against the virus in this age group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER